DiME Reveals Digital Measures For Treatment Of Atopic Dermatitis

Digital News

DiME reveals digital measures for treatment of atopic dermatitis

These resources offer a blueprint for future development of digital endpoints

The Digital Medicine Society (DiME) has released a new set of open-access resources to advance the use of nocturnal scratch in the treatment of atopic dermatitis (AD), according to Pharma Phorum.

Nocturnal scratch aims to offer “new ways of measuring night-time scratching, using new digital tools to improve measurement of this distressing facet of AD.”

Kerry Capozza, Founder and Executive Director of Global Parents for Eczema Research explains, “There’s no easy solution, unless the eczema can be treated and brought under control”.

As it stands, no new medical product has been approved on the basis of a digital endpoint. DiMe has collaborated with founding partners Abbvie, Janssen, Novartis, Pfizer, and UCB, along with project collaborators Advancing Innovation in Dermatology, Almirall, Eli Lilly, GSK, Leo Pharma, and Sanofi. DiMe hopes nocturnal scratch will enact a shift in understanding, leading to industry alignment and acceptance.

Nocturnal scratch’s widespread implementation aims to establish a firmer digital groundwork for future clinical research, technology development, and reimbursement decisions in the dermatological field, therefore improving the lives of AD patients and caregivers.

The open-access resources were developed over a period of nine months, based on a mixedmethods study and comprehensive literature review, a series of workshops and focus groups with payers, as well as meeting with regulators.

It is anticipated that this will serve as a “blueprint for the broader development and deployment of digital endpoints in medical product development.”

NICE recommends nine digital treatment options for depression and anxiety

The National Institute for Health and Care Excellence (NICE) has recommended six digitally enabled therapies for adult patients with anxiety disorders and three digitally enabled therapies for adult patients with depression for use within the NHS while further data is gathered.

Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins

French pharmaceutical company Servier and US-based causal AI and digital twins company Aitia have announced a collaboration to create digital twins as an aid to help treat pancreatic cancer. This collaboration builds on a previous multiple myeloma one that was announced in 2022.

Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device

Bristol Myers Squibb and Viz.ai, an AI-powered medical imaging company, have signed a deal to use AI to detect and triage patients with suspected hypertrophic cardiomyopathy (hcm).

Sooma receives FDA Breakthrough Device designation for depression therapy device

Finnish company Sooma medical has received breakthrough device designation by the FDA for its portable, at-home neuromodulation device to treat depression.

Elon Musk’s Neuralink rejected by FDA for human trials

The FDA has reportedly rejected a bid by Elon Musk’s Neuralink in which it proposed the initiation of human testing for its brain chip implants. The company has been working on brain implants that allow for a computer-brain interface, which could allegedly restore vision to the blind and help paralysed people to walk again.

NICE recommends nine digital treatment options for depression and anxiety

Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins

Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device

Sooma receives FDA Breakthrough Device designation for depression therapy device

Elon Musk’s Neuralink rejected by FDA for human trials

Pharmafocus

Categories

Social Footprints